

ImmunoBlue

IB-T cells for Glioblastoma



Lizie Sweeney, PhD
CEO



Rohan Fernandes, PhD
CSO, Founder



Varnika Roy, PhD
Head of Development


ImmunoBlue is led by a multidisciplinary team with deep expertise in bioengineering, cell therapy, and translational development. Combined, >\$5M raised, 60+ publications, and 6+ patents with exclusive IP option.

PROBLEM: GBM is fatal

- Glioblastoma (GBM) is the most common malignant brain tumor in the U.S. (>13,000 new cases/year).
- Outcomes remain extremely poor: **five-year survival is ~7.5%, and >90% of patients relapse.**
- Standards of care (surgery, radiation, chemo) have not changed in decades and fail to deliver durable disease control.

SOLUTION: IB-T cells for GBM

- IB-T cells^{1,2} are a **first-in-class autologous T cell therapy.**
- Nanoparticle-driven photothermal conditioning of a patient's own tumor tissue reveals the full set of immune signals, enabling expansion of T cells that recognize many tumor targets simultaneously.
- The result is a personalized, multi-targeted immune response that is harder for tumors to escape.
- This platform extends beyond GBM to other solid tumors.



MARKET SIZE: \$6B


- Entry market is 2nd line therapy for recurrent GBM.
- At ~12,564 recurrent patients per year in the US and the current benchmark price of T cell therapy at \$475,000, **estimated annual addressable market of \$6B.**
- Market expansion into newly diagnosed disease and other solid tumor indications.

COMPETITIVE ADVANTAGE

	Activated and scalable	Multiple targets	Personalized	Novel antigen discovery
CAR T cells	✓	✗	✗	✗
Multi-antigen-specific T cells	✓	✓	✗	✗
Tumor-infiltrating lymphocytes (TILs)	✗	✓	✓	✗
IB-T cells	✓	✓	✓	✓

PRECLINICAL IN VIVO VALIDATION

IB-T cells cure >80% of mice with GBM



DEVELOPMENT PLAN: Targeting \$10M Raise

- NCI Phase I & II STTR funding secured (**\$2.7M**)
- IND-enabling studies and GMP manufacturing underway
- Clinical partners (Rutgers Cancer Institute) and advisory team in place
 - Experts in neurosurgery, neuro-oncology, cellular immunotherapy, and cellular manufacturing
- Orphan Drug Designation and IND submission planned
- **Seeking \$10M to fund first-in-human Phase 1 clinical trial in recurrent GBM**

¹ Sweeney, et al. *Cytotherapy*, 2023.

² Sweeney, et al. *Bioengineering & Translational Medicine*, 2023.